The metabolic shift from OXPHOS to glycolysis due to genetic ablation of p32 has been reported in breast cancer cells10 and dendritic cells43, and similarly the p32−/− MEFs showed a glycolytic metabolic shift (Fig. 7a,b). This evidence concerns the gene C1QBP and breast carcinoma.